Drug Profile
Prostate cancer subunit vaccine - Progenics
Alternative Names: Recombinant soluble PSMA protein vaccine; rsPSMALatest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer Progenics Pharmaceuticals
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for phase-I development in Prostate-cancer in USA (SC)
- 22 Apr 2021 Phase-I development is ongoing for Prostate cancer in the US (Alphavax pipeline, April 2021)
- 16 Jun 2020 Progenics Pharmaceuticals has been acquired by Lantheus Holdings